Concepedia

Author

Akichika Ozeki

Eli Lilly (Japan)ORCID

Also Known As

Akichika OZEKI, Akichika Ozeki

31

Publications

430

Citations

10

H-Index

14

Concepts

All Affiliations

Eli Lilly (Japan)Eli Lilly (United States)Tokyo Dental College Ichikawa General HospitalFujitsu (Japan)Tominaga hospital
AO

About

Akichika Ozeki is an author at Eli Lilly (Japan) specializing in pharmacotherapy, clinical trials, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

184

2

Pharmacology

3

3

184

3

Diabetes

2

2

143

4

Health Sciences

1

1

41

5

Neurology

1

1

41

Akichika Ozeki

×

12

Publications

359

Citations

10

H-Index

YearCitations

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial

Takashi Kadowaki, Rina Chin, Akichika Ozeki,

The Lancet Diabetes & Endocrinology

2022

115

Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial

Fumihiko Sakai, Akichika Ozeki, Vladimir Skljarevski

Cephalalgia Reports

2020

41

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia

Takaki Yoshikawa, Kei Muro, Kohei Shitara,

JAMA Network Open

2019

38

A long-term open-label safety study of galcanezumab in Japanese patients with migraine

Koichi Hirata, Takao Takeshima, Fumihiko Sakai,

Expert Opinion on Drug Safety

2021

29

A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial

Masanori Emoto, Yasuo Terauchi, Akichika Ozeki,

Endocrine Journal

2015

28

Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial

Mika Komori, Akichika Ozeki, Yuka Tanji,

The Journal of Headache and Pain

2024

24

Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study

Mamoru Shibata, Tomomi Nakamura, Akichika Ozeki,

Journal of Pain Research

2020

20

Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial

Mamoru Shibata, Atsuko Nihira, Yuka Tanji,

Neurology and Therapy

2023

18

Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials

Hirofumi Tokuoka, Hitoshi Takahashi, Akichika Ozeki,

Journal of Affective Disorders

2016

15

Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial

Hisaka Igarashi, Mamoru Shibata, Akichika Ozeki,

Neurology and Therapy

2022

11

Page 1